AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Praxis Precision Medicines Inc (NASDAQ:PRAX)
278.93 USD
+20.850 8.079%| Previous Close (in USD) | 258.08 |
|---|---|
| Change | +20.850 8.079% |
| 52 W H/L (in USD) | 67.210/12.450 |
| EBITDA (in USD) | -129.73M |
| PE Ratio | -- |
| Volume | 676481 |
| Diluted Eps TTM | -11.27 |
| Total Assets (in USD) | 87.948M |
|---|---|
| Total Liabilities (in USD) | 18.279M |
| Revenue TTM (in USD) | 2.195M |
| Cash (in USD) | 81.3M |
| Market Cap (in USD) | 773.448 M |
| Revenue Per Share TTM | 0.239 |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Employees: 82
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Marcio Souza M.B.A. | Pres, CEO & Director | 1980 |
| 2. | Ms. Nicole Sweeny | Chief Commercial Officer | 1975 |
| 3. | Dr. Steven Petrou B.Sc. (Hons.), Ph.D. | Co-Founder & Chief Scientific Officer | NA |
| 4. | Mr. Timothy Edwin Kelly | CFO & Treasurer | 1973 |
| 5. | Lauren Mastrocola | VP of Fin. & Principal Accounting Officer | NA |
| 6. | Dr. Karl Hansen Ph.D. | Chief Technical Operations Officer | NA |
| 7. | Alex Kane | VP of Investor Relations & Corp. Communications | NA |
| 8. | Mr. Alex Nemiroff J.D. | Gen. Counsel & Sec. | 1979 |
| 9. | Ms. Kelly McCue | Chief People Officer | NA |
| 10. | Ms. Alyssa J. S. Wyant | Chief Regulatory & Quality Officer | 1975 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -214.029M | -167.061M | -61.828M | -35.596M | -26.402M |
| Minority Interest | - | - | - | - | - |
| Net Income | -213.072M | -166.879M | -61.82M | -35.512M | -26.535M |
| Selling General Administrative | 59.946M | 47.075M | 16.992M | 6.232M | 3.899M |
| Gross Profit | - | - | - | - | - |
| Reconciled Depreciation | 0.419M | 0.182M | 0.05M | 0.037M | 0.001M |
| Ebit | -215.405M | -167.514M | -62.018M | -35.789M | -26.275M |
| Ebitda | -214.986M | -167.332M | -61.968M | -35.559M | -26.274M |
| Depreciation And Amortization | 0.419M | 0.182M | 0.05M | 0.23M | 0.001M |
| Operating Income | -214.986M | -167.332M | -61.968M | -35.789M | -22.719M |
| Other Operating Expenses | 214.986M | 167.332M | 61.968M | 35.789M | 22.719M |
| Interest Expense | 0.419M | 0.182M | 0.19M | 0M | 0.127M |
| Tax Provision | 0M | 0M | -0.008M | -0.084M | 0.133M |
| Interest Income | - | - | 0.14M | 0.193M | 0.092M |
| Net Interest Income | - | - | 0.14M | 0.193M | -0.035M |
| Income Tax Expense | -0.957M | -0.182M | -0.008M | -0.084M | 0.133M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 214.986M | 167.332M | 61.968M | 35.789M | 22.719M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 0.957M | 0.271M | 0.14M | 0.193M | -3.648M |
| Net Income From Continuing Ops | -214.029M | -167.061M | -61.82M | -35.512M | -26.535M |
| Net Income Applicable To Common Shares | -214.029M | -167.061M | -70.323M | -40.682M | -29.223M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 87.948M | 115.128M | 292.747M | 303.177M | 47.694M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 3.58M | 10.351M | 11.498M | 5.718M | 0.681M |
| Total Liab | 18.279M | 39.022M | 41.935M | 15.72M | 7.581M |
| Total Stockholder Equity | 69.669M | 76.106M | 250.812M | 287.457M | 40.113M |
| Other Current Liab | 7.416M | 14.845M | 22.533M | 10.869M | 3.455M |
| Common Stock | 0.013M | 0.005M | 0.005M | 0.004M | 0.001M |
| Capital Stock | 0.013M | 0.005M | 0.005M | 0.004M | 0.001M |
| Retained Earnings | -653.921M | -530.644M | -316.615M | -149.554M | -81.009M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.416M | 0.472M | 0.769M | 0.62M |
| Cash | 81.3M | 61.615M | 138.704M | 296.608M | 44.815M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 15.749M | 35.522M | 37.624M | 15.72M | 6.818M |
| Current Deferred Revenue | 1.392M | 5M | - | - | - |
| Net Debt | -78.805M | -57.11M | -134.393M | -295.845M | -43.356M |
| Short Term Debt | 1.126M | 1.005M | 4.311M | 0.763M | 0.696M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 2.495M | 4.505M | 4.311M | 0.763M | 1.459M |
| Other Stockholder Equity | 723.577M | 606.918M | 567.598M | 437.007M | -121.083M |
| Property Plant Equipment | - | 0.971M | 4.866M | 0.836M | 1.578M |
| Total Current Assets | 84.88M | 110.84M | 287.409M | 302.326M | 45.496M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 0M | 38.874M | 137.207M | - | - |
| Net Receivables | - | - | - | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 5.815M | 14.672M | 10.78M | 4.088M | 2.667M |
| Accumulated Other Comprehensive Income | - | -0.173M | -0.176M | -303.177M | -0.038M |
| Non Currrent Assets Other | 0.416M | 0.416M | 0.472M | 0.015M | 0.62M |
| Non Current Assets Total | 3.068M | 4.288M | 5.338M | 0.851M | 2.198M |
| Capital Lease Obligations | 2.495M | 3.5M | 4.311M | 0.763M | 1.459M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 97.333M | -139.47M | -139.47M | -0.103M | -0.063M |
| Total Cashflows From Investing Activities | 96.889M | -140.52M | 0.004M | -0.103M | -0.063M |
| Total Cash From Financing Activities | 10.465M | 107.586M | 304.416M | 60.388M | 37.804M |
| Net Income | -214.029M | -167.061M | -61.82M | -35.512M | -26.535M |
| Change In Cash | -77.689M | -157.488M | 251.793M | 26.865M | 17.02M |
| Begin Period Cash Flow | 139.72M | 297.208M | 45.415M | 18.55M | 1.53M |
| End Period Cash Flow | 62.031M | 139.72M | 297.208M | 45.415M | 18.55M |
| Total Cash From Operating Activities | -185.043M | -124.554M | -52.623M | -33.42M | -20.721M |
| Depreciation | 0.419M | 0.182M | 0.05M | 0.037M | 0.001M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | 1.164M | 100.86M | -30M | - | - |
| Other Cashflows From Financing Activities | 0.904M | 1.872M | 133.53M | -0.103M | 37.804M |
| Capital Expenditures | 0.444M | 1.05M | 0.004M | 0.103M | 0.063M |
| Change In Working Capital | -1.781M | 16.133M | 3.24M | 0.745M | 1.459M |
| Other Non Cash Items | 1.755M | 1.412M | 0.696M | 0.642M | 0.127M |
| Free Cash Flow | -185.487M | -125.604M | -52.619M | -33.523M | -20.784M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 520522 |
| 2. | BlackRock Extended Mkt Composite | 2 years ago | 303703 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 237861 |
| 4. | Biotech Growth Ord | 2 years ago | 190100 |
| 5. | Renaissance Global Health Care | 2 years ago | 173868 |
| 6. | T. Rowe Price New Horizons | 2 years ago | 133805 |
| 7. | US Small-Cap Growth II Equity Comp | 2 years ago | 133805 |
| 8. | Franklin Biotechnology Discv A(acc)USD | 2 years ago | 94885 |
| 9. | Fidelity Extended Market Index | 2 years ago | 72297 |
| 10. | Invesco Dorsey Wright SmallCap Momt ETF | 2 years ago | 71412 |
| 11. | Franklin Biotechnology Discovery A | 2 years ago | 50404 |
| 12. | Heptagon Driehaus US Micro Cap Eq C$ Acc | 2 years ago | 47293 |
| 13. | BlackRock Extended Equity Market K | 2 years ago | 27220 |
| 14. | iShares Micro-Cap ETF | 2 years ago | 27070 |
| 15. | T. Rowe Price New Horizons Tr-Z | 2 years ago | 25683 |
| 16. | Invesco Dorsey Wright Healthcare MomtETF | 2 years ago | 25144 |
| 17. | Fidelity Total Market Index | 2 years ago | 23497 |
| 18. | Driehaus Micro Cap Growth USD | 2 years ago | 21639 |
| 19. | Bridgeway Ultra-Small Company Market | 2 years ago | 20373 |
| 20. | Fidelity Series Total Market Index | 2 years ago | 17949 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Adage Capital Partners Gp LLC | 2 years ago | 1393028 |
| 2. | Cormorant Asset Management, LLC | 2 years ago | 1310000 |
| 3. | Perceptive Advisors LLC | 2 years ago | 821589 |
| 4. | Vanguard Group Inc | 2 years ago | 744069 |
| 5. | Verition Fund Managegment, LLC | 2 years ago | 545408 |
| 6. | T. Rowe Price Associates, Inc. | 2 years ago | 535999 |
| 7. | Partner Fund Management LP | 2 years ago | 477605 |
| 8. | Orbimed Advisors, LLC | 2 years ago | 460512 |
| 9. | Velan Capital Investment Management LP | 2 years ago | 350666 |
| 10. | Kingdon Capital Management LLC | 2 years ago | 350000 |
| 11. | 5AM Venture Management, LLC | 2 years ago | 340000 |
| 12. | HHG PLC | 2 years ago | 310059 |
| 13. | Bank of America Corp | 2 years ago | 278862 |
| 14. | Driehaus Capital Management LLC | 2 years ago | 266496 |
| 15. | Octagon Capital Advisors LP | 2 years ago | 260000 |
| 16. | Tri Locum Partners LP | 2 years ago | 248761 |
| 17. | LAURION CAPITAL MANAGEMENT LP | 2 years ago | 225000 |
| 18. | Vestal Point Capital LP | 2 years ago | 210000 |
| 19. | CIBC Global Asset Management Inc | 2 years ago | 192304 |
| 20. | SILVERARC CAPITAL MANAGEMENT, LLC | 2 years ago | 190556 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...